Li-Cor Biosciences of Lincoln, Neb., and Spectros Corp. of Portola Valley, Calif., have announced a nonexclusive licensing and supply agreement to couple the former company’s IRDye 800CW to the latter’s targeted biomarkers. Additionally, the companies have agreed to develop targeted fluorescent contrast agents for real-time imaging and treatment of prostate and ovarian cancer.